01 March 2023

Genpharm and Apellis Pharmaceuticals Enter in an Exclusive Agreement


Dubai, March 1st 2023


Genpharm is pleased to announce it has entered into an exclusive agreement with Apellis Pharmaceuticals, Inc. to market and sell intravitreal pegcetacoplan upon regulatory approval in United Arab Emirates (UAE), Saudi Arabia, Oman, Qatar, Kuwait, and Bahrain. The FDA recently approved intravitreal pegcetacoplan in the United States for the treatment of geographic atrophy (GA), an advanced stage of age-related macular degeneration. GA is an irreversible disease that impacts approximately five million patients worldwide and a leading cause of blindness.

“We continue to build our strategic partnerships with our core mission in mind,” say Karim Smaira and Kamel Ghammachi the co-founders and managing partners of Genpharm. “Our mission is to facilitate access to the latest therapeutic innovations for patients in the MENA region, and intravitreal pegcetacoplan provides us with an opportunity to do so upon regulatory approval. We look forward to working closely with the ophthalmology community in the GCC to raise awareness and support them in their management of GA”.


About Apellis Pharmceuticals 

At Apellis, we combine courageous science and compassion to develop life-changing medicines for some of the most challenging diseases patients face. We Advance Courageous Science Our goal is to transform treatment for a broad range of debilitating diseases by controlling a part of the immune system known as the complement cascade.  We ushered in the first new class of complement medicine in 15 years, and now have two approved medicines targeting C3, the central protein in the cascade. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases.
Learn some more at
Latest News